Updated Jul 18, 2026
/Verra Mobility shareholders can seek lead plaintiff role in securities fraud class action, law firm says/Berger Montague notifies Futu Holdings investors of class action and participation deadline/Elong Power Holding closes US$6.6 million public offering on Nasdaq/Hub Group class action spans April 2023 to May 2026 as Robbins LLP seeks lead plaintiff/Jinxin Technology regains Nasdaq minimum bid price compliance/IMB Partners completes growth investment in Strategic Land Services/Verra Mobility shareholders can seek lead plaintiff role in securities fraud class action, law firm says/Berger Montague notifies Futu Holdings investors of class action and participation deadline/Elong Power Holding closes US$6.6 million public offering on Nasdaq/Hub Group class action spans April 2023 to May 2026 as Robbins LLP seeks lead plaintiff/Jinxin Technology regains Nasdaq minimum bid price compliance/IMB Partners completes growth investment in Strategic Land Services

Virax Biolabs closes $3.3 million preferred option exercise, issuing up to 548,000 ordinary shares

LONDON, July 10. A $3.3 million exercise of preferred investment options closed at Virax Biolabs Group Limited on Thursday, the company said. The close covered the purchase of up to 548,000 ordinary shares. The London-based company, which trades on Nasdaq under the ticker VRAX, had previously announced the deal.

By Owen Gallagher2 min read
Share

Key takeaways

  • Virax Biolabs Group Limited closed a $3.3 million exercise of preferred investment options on Thursday, July 10, 2026.
  • The exercise covered the purchase of up to 548,000 ordinary shares tied to the company's preferred investment options.
  • The $3.3 million figure represents gross proceeds, with no fees or expenses specified in the release.
  • Virax Biolabs is a London-based company listed on the Nasdaq Capital Market under the ticker symbol VRAX.
  • The company had previously announced the deal before its closing was confirmed.

LONDON, July 10. A $3.3 million exercise of preferred investment options closed at Virax Biolabs Group Limited on Thursday, the company said. The close covered the purchase of up to 548,000 ordinary shares. The London-based company, which trades on Nasdaq under the ticker VRAX, had previously announced the deal.

Transaction details

The instruments exercised were preferred investment options tied to ordinary shares of Virax Biolabs Group Limited, according to the company's release. The $3.3 million represents gross proceeds. The release did not specify fees or expenses to be deducted from that figure.

The ordinary shares carry a par value, the filing states, though the specific amount was not included in the release summary.

About Virax Biolabs Group Limited

Virax Biolabs Group Limited is listed on the Nasdaq Capital Market under the ticker symbol VRAX and is headquartered in London. The closing was confirmed in a release dated July 10, 2026.


Note: The source summary was truncated and provided limited disclosures. This article reflects only the facts contained in the available text.

Related reading

Frequently asked

What did Virax Biolabs announce on July 10, 2026?

The company said a $3.3 million exercise of preferred investment options had closed, covering the purchase of up to 548,000 ordinary shares.

Does the $3.3 million include fees?

The $3.3 million represents gross proceeds, and the release did not specify any fees or expenses to be deducted from that figure.

Where is Virax Biolabs based and how is it traded?

Virax Biolabs Group Limited is headquartered in London and trades on the Nasdaq Capital Market under the ticker symbol VRAX.

How many ordinary shares could be issued from the exercise?

The close covered the purchase of up to 548,000 ordinary shares of Virax Biolabs Group Limited.